We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
NovAliX Enters into Alliance with Kyowa Hakko Kirin
News

NovAliX Enters into Alliance with Kyowa Hakko Kirin

NovAliX Enters into Alliance with Kyowa Hakko Kirin
News

NovAliX Enters into Alliance with Kyowa Hakko Kirin

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NovAliX Enters into Alliance with Kyowa Hakko Kirin"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

NovAliX SAS has announced that it has entered into a fragment-based drug discovery alliance with Kyowa Hakko Kirin Co., Ltd., Japan.

Within the alliance, the companies will collaborate to develop novel drug candidates against protein-protein interaction targets.

NovAliX will generate novel lead candidates using the broad spectrum of its biophysical capabilities and its medicinal chemistry expertise.

Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments and milestones.

Stephan Jenn, President of NovAliX, stated, "For NovAliX this drug discovery alliance represents a significant development of our established relation with Kyowa Hakko Kirin. This drug discovery collaboration with a leading Japanese pharmaceutical company also confirms the quality of our discovery platforms and its ability to deliver valuable lead candidates."

Advertisement